Shanghai HeartCare Medical Technology Corporation Limited

Shanghai HeartCare Medical Technology Corporation Limited is a China-based neuro-interventional medical device pioneer striving to redefine the therapeutic and preventive paradigm of stroke. Leveraging integrated capabilities in R&D, manufacturing, and commercialization, the company aims to reduce the mortality rate and improve the prognosis of stroke in China and globally through innovative product candidates. With a broad portfolio of 23 commercialized products and product candidates covering the neurointerventional market, including ischemic and hemorrhagic stroke treatments, the company has obtained NMPA approvals for four ischemic stroke treatment devices. It also plans to commercialize nine late-stage and 10 early-stage product candidates in the coming years, further expanding offerings for unmet needs of stroke patients. With a focus on innovation and a comprehensive product portfolio, including global-first and domestic-first neuro-interventional devices, Shanghai HeartCare Medical Technology Corporation Limited aims to lead the revolution in stroke treatment. Founded in 2016, the company is a promising player in the medical technology industry.